Table 2.
Associations between continuous cardiometabolic risk factors and MDCT-acquired fat depots (as determined by stepwise forward selection).
| Cardio- metabolic Risk Factors |
Model Typea |
Effect Size |
MDCT-Acquired Fat Depots | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Subcutaneous Adipose Tissue |
Visceral Adipose Tissue |
Intramuscular Fat |
Intrathoracic Fat |
Pericardial Fat |
Thoracic Periaortic Fat |
Intrahepatic Fat |
Renal Sinus Fat |
|||
| BMI | MV | β (95% CI) | 3.60 (3.48,3.73) | 1.75 (1.61,1.90) | 0.14 (0.03,0.26) | |||||
| P Value | <.001 | <.001 | 0.02 | |||||||
| Systolic Blood Pressureb | MV | β (95% CI) | 1.75 (0.99,2.51) | 1.95 (1.02,2.87) | 0.99 (0.37,1.61) | |||||
| P Value | <.001 | <.001 | 0.002 | |||||||
| MV+ BMI | β (95% CI) | -0.07 (-1.21,1.07) | 1.12 (0.12,2.12) | 0.95 (0.34,1.57) | ||||||
| P Value | 0.91 | 0.03 | 0.002 | |||||||
| Diastolic Blood Pressureb | MV | β (95% CI) | 1.03 (0.56,1.49) | 1.71 (1.05,2.36) | -0.57 (-1.05,-0.09) | 0.49 (0.11,0.86) | 0.53 (0.08,0.97) | |||
| P Value | <.001 | <.001 | 0.02 | 0.01 | 0.02 | |||||
| MV+ BMI | β (95% CI) | 0.27 (-0.43,0.96) | 1.35 (0.66,2.05) | -0.56 (-1.03,- | 0.47 (0.10,0.84) | 0.52 (0.08,0.97) | ||||
| P Value | 0.45 | <.001 | 0.02 | 0.01 | 0.02 | |||||
| Fasting Plasma Glucosec | MV | β (95% CI) | 6.45 (5.15,7.75) | -2.26 (-3.57,-0.95) | 0.95 (0.20,1.69) | |||||
| P Value | <.001 | <.001 | 0.01 | |||||||
| MV+ BMI | β (95% CI) | 4.18 (2.62,5.74) | -2.07 (-3.37,-0.77) | 0.92 (0.18,1.66) | ||||||
| P Value | <.001 | .002 | 0.01 | |||||||
| Total Cholesterold | MV | β (95% CI) | 5.05 (2.52,7.58) | -2.91 (-5.49,-0.32) | 2.98 (1.29,4.68) | |||||
| P Value | <.001 | 0.03 | <.001 | |||||||
| MV+ BMI | β (95% CI) | 4.86 (1.92,7.80) | -2.91 (-5.50,- | 2.97 (1.27,4.67) | ||||||
| P Value | 0.001 | 0.03 | <.001 | |||||||
| LDL Cholesterold | MV | β (95% CI) | 1.70 (0.12,3.29) | 5.55 (3.05,8.04) | -2.91 (-5.26,-0.56) | |||||
| P Value | 0.04 | <.001 | 0.02 | |||||||
| MV+ BMI | β (95% CI) | 1.53 (-0.86,3.92) | 5.47 (2.85,8.09) | -2.92 (-5.27,- | ||||||
| P Value | 0.21 | <.001 | 0.02 | |||||||
| HDL Cholesterold | MV | β (95% CI) | -5.99 (-6.63,-5.36) | -1.08 (-1.74,-0.42) | ||||||
| P Value | <.001 | 0.001 | ||||||||
| MV+ BMI | β (95% CI) | -4.41 (-5.30,- | -1.08 (-1.73,-0.43) | |||||||
| P Value | <.001 | 0.001 | ||||||||
| Log Triglyceridesd | MV | β (95% CI) | 0.22 (0.18,0.25) | 0.03 (0.01,0.06) | -0.04 (-0.08,-0.01) | 0.06 (0.04,0.08) | 0.06 (0.04,0.08) | |||
| P Value | <.001 | 0.004 | 0.01 | <.001 | <.001 | |||||
| MV+ BM | β (95% CI) | 0.18 (0.14,0.23) | 0.03 (0.01,0.06) | -0.04 (-0.08,-0.01) | 0.06 (0.04,0.08) | 0.06 (0.03,0.08) | ||||
| P Value | <.001 | 0.004 | 0.02 | <.001 | <.001 | |||||
Data are shown as β coefficients (95% CIs) and p-values. The β coefficients describe the association with continuous cardiometabolic risk factor per 1 standard deviation decrement in intramuscular fat and intrahepatic fat; and per 1 standard deviation increment in other MDCT-acquired fat depots. Shaded cells indicate that the fat measures were not selected via the stepwise forward selection regression procedure.
MV model included following covariates: age, sex, current smoking, alcohol use, physical activity index, postmenopausal status (women only), and hormone replacement therapy (women only). BMI was additionally adjusted for in the models labelled “MV+BMI model.”
Antihypertensive treatment was included as a covariate for systolic and diastolic blood pressure models.
Diabetes treatment was included as a covariate for fasting plasma glucose model.
Lipid-lowering treatment was included as a covariate for total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides models. Abbreviations: BMI, body mass index; CI, confidence interval; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MDCT, multi-detector computed tomography; MV, multivariable model.